IDEAYA announces clinical collaboration with Roche for PRMT5 + pan-RAS combo in MTAP-deleted PDAC

IDEAYA Biosciences, Inc.

IDE892 (PRMT5 inhibitor) to be combined with Roche's RG6505 (pan-RAS inhibitor) in MTAP-deleted, RAS-mutant pancreatic cancer.
IDEAYA will sponsor the Phase 1 combination trial; Roche will supply RG6505.
MTAP deletion occurs in up to 40% of PDAC; almost all such cases have co-occurring RAS mutations.
Both companies retain full commercial rights to their compounds; joint governance oversees the study.
Triplet combination with IDE397 (MAT2A inhibitor) may be evaluated with joint approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.